The biennial EFMC-ISMC is a key symposium in the field of medicinal chemistry and drug discovery and it traditionally attracts around 1.000 participants both from industry and academia. The most recent EFMC-ISMC meeting took place in Slovenia (Ljubljana, 2018), while the edition initially planned for Basel, Switzerland in 2020 has been run as a Virtual Event in 2021.
The 2022 programme will cover advances in drug discovery in major therapeutic areas, including bacterial and viral infections, with a particular attention to current and emerging viral pandemics, but also neurodegenerative and cardiovascular diseases, rare diseases and cancer. EFMC-ISMC 2022 will also feature most recent advances in new technologies such as the exploitation of RNA as drug target, artificial intelligence in drug discovery, natural products-based drug discovery, DNA encoded libraries applications and the development of covalent drugs, PROTACs, and molecular glues. Innovative approaches in medicinal chemistry will be included such as the development of immunomodulating compounds or the application of affinity selection – mass spectrometry for drug discovery. In a series of dedicated sessions, the interface between chemical biology and drug discovery will be highlighted, including topics such as in vivo chemistry for target discovery and validation, molecular imaging, and photochemical approaches. Finally, particular emphasis will again be put on first time disclosures and recent highlights in medicinal chemistry.
The parallel sessions are grouped in 3 different themes:
- Chemical Biology
- Drug Discovery Projects
- Technologies
In addition, the programme contains three open sessions: First Time Disclosures (I & II) and Recent Highlights in Medicinal Chemistry. For these sessions, the talks will be selected from the submitted abstracts.
For most of the below topics, a slot in the programme will be available for an oral communication selected out of the submitted abstracts.
Chemical Biology
Addressing Cooperative Ligand Binding in Drug Discovery (EUCHEMS Session)
Chair: Prof. Luc Brunsveld, Eindhoven University of Technology, NL
Targeting Self-Associating Proteins & Biomolecular Condensates in Drug Discovery
Chair: Prof. Raphaël Frederick, UCLouvain, BE
Beyond PROTACS, Monovalent and Glues Degraders
Chair: Dr Laura M. Luh, Bayer, DE
Targeting Epigenetic Modifications in Cancer Therapy (ICBS Session)
Chair: Prof. Zaneta Nikolovska-Coleska, University of Michigan, US
Chemical Probes for Target Identification & Validation
Chair: Dr Joanna Redmond, GlaxoSmithKline, UK
in vivo Chemistry
Chair: Dr Frédéric Taran, CEA/Saclay, FR
Mining the Phosphosignaling Networks
Chair: Dr Nadia Ahmad, Charles River, UK
Drug Discovery Projects
Drug Discovery in Targeting Neurodegenerative Disorders (ACS Session)
Chair: Dr Rong Huang, Purdue University, US
Covalent Drugs
Chair: Dr Samir Jegham, Sanofi, FR
Rising Horizons of Small Molecule Immunotherapies and Beyond
Chair: Prof. Antonio Macchiarulo, University of Perugia, IT
New Treatments for Current and Future Pandemics
Chair: Prof. Ana Martinez, CSIC, ES
Time to Act Against Antimicrobial Resistance
Chair: Prof. Maria-Jesus Pérez-Pérez, Instituto de Química Médica, ES
Targeting RNA by Small Molecules
Chair: Dr Hasane Ratni, F. Hoffmann-La Roche, CH
Drugging the Undruggable: Targeting Transcription Factors (ACS Session)
Chair: Dr Anthony Romero, Oric Pharmaceuticals, US
Renaissance of Natural-Product Inspired Drug Discovery in the 21st Century
Chair: Dr Boris Vauzeilles, Institut de Chimie des Substances Naturelles, FR
Technologies
Bioanalytics for DD: New Developments and Applications of Affinity Selection – Mass Spectrometry
Chair: Dr Jean-Yves Ortholand, Edelris, FR
Innovative Synthetic Technologies for Drug Discovery
Chair: Dr Cara Brocklehurst, Novartis, CH
Hit Discovery with DNA-Encoded Libraries
Chair: Dr Andreas Brunschweiger, TU Dortmund, DE
AI in Drug Discovery (CPA Session)
Chair: Dr Jiang Hualiang, Shanghai Institute of Materia Medica, CN
Methods for Late-Stage Functionalization
Chair: Prof. Tobias Ritter, MPI für Kohlenforschung, DE
Tissue Specific Targeting Strategies of Drug Candidates
Chair: Dr Jan Willem Thuring, Janssen, BE
Radiochemistry (AFMC Session)
Chair: Prof. Norio Matsuki, University of Tokyo & AFMC President, JP
EFMC2
Session Chair to be announced
Open Sessions (selected from submitted abstracts)
First Time Disclosures (I & II)
Session Chairs to be announced
Recent Highlights in Medicinal Chemistry
Session Chair to be announced
